|Bid||2.61 x 100|
|Ask||2.96 x 100|
|Day's Range||2.83 - 2.88|
|52 Week Range||2.24 - 3.72|
|PE Ratio (TTM)||0.91|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.25|
Regeneron (REGN) announces encouraging top-line results from the phase III study evaluating Eylea injection in moderately severe to severe non-proliferative diabetic retinopathy.
JPMorgan is generally bullish on biotech and in most cases sees opportunity for longer-term upside, but its ratings strategy dictates the sidelining of lower conviction stocks. Here's a look at biotech ...
Ophthotech Corporation announced today that Kourous A. Rezaei, M.D., Chief Medical Officer, will present an overview of the Company at the Cowen and Company 38th Annual Health Care Conference in Boston, MA on Tuesday, March 13, 2018 at 9:20 a.m.
Stock Monitor: Spark Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 01, 2018 / Active-Investors.com has just released a free research report on Ophthotech Corp. (NASDAQ: OPHT ). If ...
Ophthotech (OPHT) reports better-than-expected fourth-quarter earnings but misses on sales. The company plans to use novel gene therapy to develop new treatments for ocular diseases.
On a per-share basis, the New York-based company said it had a loss of 26 cents. For the year, the company reported net income of $114.2 million, or $3.17 per share, swinging to a profit in the period. ...
Ophthotech Corporation today announced financial and operating results for the fourth quarter and full year ended December 31, 2017 and provided a business update.
Ophthotech Corporation announced today that the Company has initiated an innovative gene therapy research collaboration focused on applying novel gene therapy technology to discover and develop next-generation therapies for the treatment of ocular diseases.
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Ophthotech Corp. (NASDAQ: OPHT ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 8:00 AM Eastern Time. ...
Ophthotech Corporation today announced that it will report its fourth quarter and full year 2017 financial and operating results on Tuesday, February 27, 2018. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m.
NEW YORK, Feb. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Innospec ...
Ophthotech Corporation announced today that the first patient has been enrolled in the Phase 2b randomized, double-masked, sham-controlled clinical trial assessing the efficacy and safety of Zimura® , complement C5 inhibitor, in patients with autosomal recessive Stargardt disease .
Ophthotech Corporation announced today the election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to its Board of Directors, effective immediately.
Ophthotech Corporation announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 36th Annual J.P.
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Ophthotech Corporation breached their fiduciary duties to shareholders.
Regeneron (REGN) announced that the FDA has accepted for review the company's supplemental Biologics License Application (sBLA) for Eylea with an action date of Aug 11, 2018.
Ophthotech (OPHT) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ophthotech Corp. Here are 5 ETFs with the largest exposure to OPHT-US. Comparing the performance and risk of Ophthotech Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Vertex (VRTX) received CHMP recommendation for label expansion of Orkambi in children aged 6 to 11 years with CF who have two copies of the F508del mutation.